FDA Warning Letter Statistics 2013 Regarding Process Validation/Qualification/Calibration
In 2013, process validation was at the top of the critised deviations. Missing or insufficient process validation was quoted 15 times. The most frequent critics were made to dosage forms (five times) and the manufacture of creams (three times).
The non-existent validation of a filtration time and of a filter replacement, as well as insufficient packaging validation (filling, sealing and labelling) have been criticised too. More and more terms from the 'new' FDA Guidance of 2011 appear among the corrective measures; for example "control strategy" and "scientific evidence that your manufacturing process are capable of consistently manufacturing quality products" are required.
Deviations regarding missing or insufficient cleaning validation have been observed seven times; more precisely: the non-existent use of worst case products, handling errors in "swabbing" and missing swab recovery rates were observed and criticised.
Media fills have also been often criticised (four times). Missing hold times of vials before incubation, missing rational numbers for the non-incubating of filled vials, no documentation about the reasons for rejecting vials, and insufficient failure investigation were among the points of criticism. Interestingly, the (non-validated) hold time was necessary as the company hadn't enough resources to evaluate the media fills.
Deficiencies of qualification in manufacturing were identified 11 times and concerned (five times) missing "smoke studies" for clean room qualification: the insufficient qualification of a water facility and poor clean room design were respectively criticised once. An expired balance calibration was observed once.
Also one observation was made regarding the lack of validation for the computer software Microsoft Dynamics.
Conclusion: The analysis is similar to that of the previous years and the top deficiencies haven't changed that much. Most findings concerned process validation, and again, the majority had to do with solid forms. The number of insufficient media fills was also comparable to that of the previous years. Nevertheless, the increase of qualification deficiencies — whereby also in the past, missing or poor "smoke studies" often appeared — is apparent.
Related News
-
News PSCI Welcomes Delpharm, Samsung Biologics, and Suven as First Supplier Partners
The pharmaceutical industry continues to evolve with an increasing focus on responsible sourcing, sustainability, and collaboration across the supply chain. Under a new model to recognise suppliers within the pharmaceutical and healthcare industry that... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Eli Lilly's weight loss drugs removed from the FDA's shortage list
The US FDA have recently updated their drug shortage list. The recently released list shows that all dosage forms of Eli Lilly's weight-loss drug Zepbound and their diabetes drug Mounjaro are now available. -
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance